Company intelligence / Profile preview

Kirilys Therapeutics

San Francisco, California, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Kirilys has multiple precision oncology assets in development. Their lead compound KRLS-017 is a reversible small molecule inhibitor of CDK7 in preclinical stage, showing best-in-class potency, selectivity, and anti-tumor efficacy. KRLS-004 (ASN-004) is in Phase 1 for colorectal cancer and is an antibody-drug conjugate targeting 5T4-oncofetal glycoprotein.

Therapeutic areas: Oncology
Modalities: Small moleculesAntibody-drug conjugate (ADC)
Industry: Biotech

Drug pipeline

1 asset

KRLS-017

Unknown

Partnerships

D2G OncologyUbe Industries

Beyond the preview

Go deeper on Kirilys Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kirilys Therapeutics.

Explore the full profile